ClearPoint Neuro Inc CLPT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$8.60 down $0.09, 1.04% at close Nov 6
Last close · Previous close $8.69
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.20Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$8.60down $0.09, 1.04%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$8.69Nov 5
- Volume945.85KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume724.99KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $8.27 to $19.63; now $8.60
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CLPT trailed the S&P 500 in all 7 periods.
| Period | CLPT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CLPT: down 21.9% S&P 500: down 5.6% | CLPT trailed the S&P 500 by 16.3 percentage points Trailed |
| 3M | CLPT: down 35.8% S&P 500: down 4.1% | CLPT trailed the S&P 500 by 31.7 percentage points Trailed |
| YTD | CLPT: down 37.1% S&P 500: up 8.7% | CLPT trailed the S&P 500 by 45.8 percentage points Trailed |
| 1Y | CLPT: down 52.8% S&P 500: up 10.9% | CLPT trailed the S&P 500 by 63.7 percentage points Trailed |
| Long term | ||
| 3Y | CLPT: up 43.1% S&P 500: up 75.0% +12.7% vs +20.5% a year | CLPT trailed the S&P 500 by 31.9 percentage points Trailed |
| 5Y | CLPT: down 53.1% S&P 500: up 67.8% −14.1% vs +10.9% a year | CLPT trailed the S&P 500 by 120.9 percentage points Trailed |
| 10Y | CLPT: up 72.0% S&P 500: up 313.1% +5.6% vs +15.2% a year | CLPT trailed the S&P 500 by 241.1 percentage points Trailed |
$10,000 invested in CLPT 10 years ago (Nov 4, 2016) would be worth about $17,200 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CLPT trailed the S&P 500 in all 7 periods.
| Period | CLPT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CLPT: down 21.9% S&P 500: down 5.6% | CLPT trailed the S&P 500 by 16.3 percentage points Trailed |
| 3M | CLPT: down 35.8% S&P 500: down 4.3% | CLPT trailed the S&P 500 by 31.5 percentage points Trailed |
| YTD | CLPT: down 37.1% S&P 500: up 7.8% | CLPT trailed the S&P 500 by 44.9 percentage points Trailed |
| 1Y | CLPT: down 52.8% S&P 500: up 9.7% | CLPT trailed the S&P 500 by 62.5 percentage points Trailed |
| Long term | ||
| 3Y | CLPT: up 43.1% S&P 500: up 68.8% +12.7% vs +19.1% a year | CLPT trailed the S&P 500 by 25.7 percentage points Trailed |
| 5Y | CLPT: down 53.1% S&P 500: up 56.9% −14.1% vs +9.4% a year | CLPT trailed the S&P 500 by 110.0 percentage points Trailed |
| 10Y | CLPT: up 72.0% S&P 500: up 252.6% +5.6% vs +13.4% a year | CLPT trailed the S&P 500 by 180.6 percentage points Trailed |
$10,000 invested in CLPT 10 years ago (Nov 4, 2016) would be worth about $17,200 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$29.60
Closing high on . Now 70.9% below that record.
Split-adjusted daily closes since Aug 8, 2016.
Stock splits
CLPT hasn’t split since its price history begins in 2016.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $45.49Mup 32.5%
- Net income
- −$36.14M
- Diluted EPS
- −$1.20
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $7.77M | −$5.39M | −$0.20 |
| Q1 FY25 (Mar 31, 2025) | $8.49M | −$6.03M | −$0.22 |
| Q2 FY25 (Jun 30, 2025) | $9.22M | −$5.84M | −$0.21 |
| Q3 FY25 (Sep 30, 2025) | $8.86M | −$5.89M | −$0.21 |
| Q4 FY25 (Dec 31, 2025) | $10.41M | −$7.79M | −$0.26 |
| Q1 FY26 (Mar 31, 2026) | $12.13M | −$9.55M | −$0.32 |
| Q2 FY26 (Jun 30, 2026) | $10.88M | −$11.34M | −$0.38 |
| Q3 FY26 (Sep 30, 2026) | $12.08M | −$7.46M | −$0.24 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $16.30M | −$14.41M | −$0.69 |
| FY22 (Dec 31, 2022) | $20.55M | −$16.44M | −$0.68 |
| FY23 (Dec 31, 2023) | $23.96M | −$22.09M | −$0.90 |
| FY24 (Dec 31, 2024) | $31.39M | −$18.91M | −$0.70 |
| FY25 (Dec 31, 2025) | $36.97M | −$25.54M | −$0.90 |
Margins
- Gross 61.4%
- Operating −70.6%
- Net −79.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$33.22MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$32.17MLast 12 months
- Capital spending$1.05MLast 12 months
- −73.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $23.55MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $46.18MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$73.70MAs of Sep 30, 2026
- Net debt$27.52MAs of Sep 30, 2026
- 6.76As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 2.70As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −170.2%Last 12 months
Over the last 12 months, ClearPoint Neuro lost money: its net loss was 170.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −37.0%Last 12 months
Over the last 12 months, ClearPoint Neuro’s net loss was 37.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About ClearPoint Neuro Inc
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CLPT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CLPT stock FAQ
What is CLPT stock’s price today?
ClearPoint Neuro (CLPT) traded at $8.60 at the close on , down $0.09 (1.04%) from the previous close of $8.69. Over the past 52 weeks it has traded between $8.27 and $19.63.
If you invested $1,000 in CLPT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CLPT on would be worth about $1,720 at the close on , a total return of +72.0%. The same $1,000 would be worth $469 if invested five years ago and $472 if invested one year ago. Past performance doesn’t predict future returns.
What is CLPT’s P/E ratio?
CLPT’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.20).
How much revenue does ClearPoint Neuro make?
ClearPoint Neuro reported $45.5 million of revenue over the four quarters to , up 32.5% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $12.1 million, up 36.3% from a year earlier.
Is ClearPoint Neuro profitable?
Not over the four quarters to . ClearPoint Neuro reported a net loss of $36.1 million across those four quarters on $45.5 million of revenue.
What are CLPT’s earnings per share?
CLPT’s diluted earnings per share were −$1.20 over the four quarters to , compared with −$0.84 in the twelve months before. The latest quarter (Q3 FY26) brought −$0.24 per share, against −$0.21 a year earlier (how EPS works).
Does CLPT pay a dividend?
ClearPoint Neuro hasn’t paid a dividend in the last twelve months.
What is CLPT’s 52-week high and low?
Over the past 52 weeks CLPT has traded as low as $8.27 and as high as $19.63. At $8.60 at the close on , it is 56.2% below that high and 4.0% above the low.
What is CLPT’s all-time high?
CLPT’s highest closing price was $29.60 on , adjusted for stock splits. At $8.60 at the close on , it is 70.9% below that record.
Has CLPT stock ever split?
No. CLPT hasn’t split since its price history begins in 2016.
How has CLPT stock performed?
Including dividends and measured to the close on , CLPT has returned −37.1% so far this year and −52.8% over the past year, and −53.1% over five years (−14.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is ClearPoint Neuro in?
ClearPoint Neuro is in the Healthcare sector and the Medical Devices industry, and is headquartered in California, USA.
What exchange does CLPT trade on?
ClearPoint Neuro trades on the Nasdaq under the ticker symbol CLPT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.